Evidence map›Paper›PMID 34446925›Full record

ArticleGenetics in medicine : official journal of the American College of Medical Genetics2021

Expanded phenotype of AARS1-related white matter disease.

Guy Helman, Marisa I Mendes, Francesco Nicita, Lama Darbelli, Omar Sherbini, Travis Moore, Alexa Derksen, Amy Pizzino, Rosalba Carrozzo, Alessandra Torraco and 27 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Genetics in medicine : official journal of the American College of Medical Genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Rigorous genetic diagnosis review in natural history studies.Orphanet journal of rare diseases · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. The Primary Microglial Leukodystrophies: A Review.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

37 authors at 20 institutions in 8 countries.

Guy HelmanMurdoch Children's Research Institute, The Royal Children's Hospital, Parkville, VIC, Australia.
Marisa I MendesMetabolic Unit, Department of Clinical Chemistry, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Francesco NicitaDepartment of Neurosciences, Unit of Muscular and Neurodegenerative Disorders, Laboratory of Molecular Medicine, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Lama DarbelliDepartment of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada.
Omar SherbiniDivision of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Travis MooreDepartment of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada.
Alexa DerksenDepartment of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada.
Amy PizzinoDivision of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Rosalba CarrozzoDepartment of Neurosciences, Unit of Muscular and Neurodegenerative Disorders, Laboratory of Molecular Medicine, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Alessandra TorracoDepartment of Neurosciences, Unit of Muscular and Neurodegenerative Disorders, Laboratory of Molecular Medicine, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Michela CatterucciaDepartment of Neurosciences, Unit of Muscular and Neurodegenerative Disorders, Laboratory of Molecular Medicine, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Chiara AielloDepartment of Neurosciences, Unit of Muscular and Neurodegenerative Disorders, Laboratory of Molecular Medicine, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Paola GoffriniDepartment of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy.
Sonia FigucciaDepartment of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy.
Desiree E C SmithMetabolic Unit, Department of Clinical Chemistry, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Kinga HadzsievDepartment of Medical Genetics, University of Pécs, Pécs, Hungary.
Andreas HahnDepartment of Child Neurology, Justus-Liebig-University, Giessen, Germany.
Saskia BiskupPraxis fuer Humangenetik and CeGaT GmbH, Tuebingen, Germany.
Ines BrösseDivision of Child Neurology and Inherited Metabolic Diseases, Centre for Paediatrics and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Urania KotzaeridouDivision of Child Neurology and Inherited Metabolic Diseases, Centre for Paediatrics and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Darja GauckInstitute of Medical Genetics and Applied Genomics, University of Tuebingen, Tuebingen, Germany.
Theresa A GrebeDivision of Genetics and Metabolism, Department of Child Health, Phoenix Children's Hospital, University of Arizona College of Medicine, Phoenix, AZ, USA.
Frances ElmslieSouth West Thames Regional Genetics Service, St George's University Hospital, London, UK.
Karen StalsMolecular Genetics Department, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
Rajat GuptaDepartment of Neurology, Birmingham Children's Hospital, Birmingham, UK.
Enrico BertiniDepartment of Neurosciences, Unit of Muscular and Neurodegenerative Disorders, Laboratory of Molecular Medicine, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Isabelle ThiffaultChildren's Mercy Kansas City, Center for Pediatric Genomic Medicine, Kansas City, MO, USA.
Ryan J TaftIllumina, Inc, San Diego, CA, USA.
Raphael SchiffmannBaylor Scott & White Research Institute, Dallas, TX, USA.
Ulrich BrandlDepartment of Neuropediatrics, Jena University Hospital, Jena, Germany.
Tobias B HaackInstitute of Medical Genetics and Applied Genomics, University of Tuebingen, Tuebingen, Germany.
Gajja S SalomonsMetabolic Unit, Department of Clinical Chemistry, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Cas SimonsMurdoch Children's Research Institute, The Royal Children's Hospital, Parkville, VIC, Australia.
Geneviève BernardDepartment of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada.
Marjo S van der KnaapDepartment of Child Neurology, Emma Children's Hospital, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam and Amsterdam Neuroscience, Amsterdam, The Netherlands.
Adeline VanderverDivision of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA. vandervera@email.chop.edu.
Ralf A HusainDepartment of Neuropediatrics, Jena University Hospital, Jena, Germany. Ralf.Husain@med.uni-jena.de.
Bambino Gesù Children's Hospital · ITChildren's Hospital of Philadelphia · USVrije Universiteit Amsterdam · NLJena University Hospital · DEMcGill University · CAMcGill University Health Centre · CAUniversity of Parma · ITUniversity of Tübingen · DEAmsterdam Neuroscience · NLBaylor Scott & White Health · USBirmingham Children's Hospital · GBHeidelberg University · DEIllumina (United States) · USPhoenix Children's Hospital · USPraxis für Humangenetik Tübingen · DERoyal Children's Hospital · AURoyal Devon & Exeter NHS Foundation Trust · GBSt George's Hospital · GBUniversity Hospital Heidelberg · DEUniversity of Giessen · DE

Funding

CIHR 201610PJT-377869
6 · The paper itself

Abstract

purposeRecent reports of individuals with cytoplasmic transfer RNA (tRNA) synthetase-related disorders have identified cases with phenotypic variability from the index presentations. We sought to assess phenotypic variability in individuals with AARS1-related disease.

methodsA cross-sectional survey was performed on individuals with biallelic variants in AARS1. Clinical data, neuroimaging, and genetic testing results were reviewed. Alanyl tRNA synthetase (AlaRS) activity was measured in available fibroblasts.

resultsWe identified 11 affected individuals. Two phenotypic presentations emerged, one with early infantile-onset disease resembling the index cases of AARS1-related epileptic encephalopathy with deficient myelination (n = 7). The second (n = 4) was a later-onset disorder, where disease onset occurred after the first year of life and was characterized on neuroimaging by a progressive posterior predominant leukoencephalopathy evolving to include the frontal white matter. AlaRS activity was significantly reduced in five affected individuals with both early infantile-onset and late-onset phenotypes.

conclusionWe suggest that variants in AARS1 result in a broader clinical spectrum than previously appreciated. The predominant form results in early infantile-onset disease with epileptic encephalopathy and deficient myelination. However, a subgroup of affected individuals manifests with late-onset disease and similarly rapid progressive clinical decline. Longitudinal imaging and clinical follow-up will be valuable in understanding factors affecting disease progression and outcome.

Indexed as

LeukoencephalopathiesCross-Sectional StudiesDisease ProgressionHumansPhenotype

Identifiers

PMID34446925
OpenAlexW3196203517

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.